TICKERNERD
Menu
UTHRUTHRHealthcare · Drug Manufacturers - Specialty & Generic

UTHR Stock Forecast: United Therapeutics Corp. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$500
−0.31% on the day

The 15 Wall Street analysts covering United Therapeutics Corp. hold a median 12-month price target of $685 — +37.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$21.4B
Ticker Nerd rank
82 / 100
Median analyst target
$685
Analysts covering
15
Total return, dividends reinvested
1W
−7.3%
1M
−5.1%
YTD
+2.6%
1Y
+60.1%
From 52W high
−16.3%
From 52W low
+64.0%
$305
$597
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

UTHR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores United Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
98
Quality
91
Issuance
87
Momentum
77
Accruals
64
Growth
45
Revisions
37
Size
10

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (37): Analysts have, on balance, been cutting their forecasts.

Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

UTHR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UTHR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$400$500$600$700$800Oct 25Jan 26Apr 26Jul 26UTHRHigh $725Median $685Low $515

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
12 Buy3 Hold0 Sell
Low $515Median $685High $725

The green dot is the last close — the median target sits +37.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Aug 2026RBC CapitalMaintainsOutperform$704 → $677
23 July 2026JP MorganMaintainsOverweight$685 → $687
23 July 2026JP MorganMaintainsOverweight—
10 July 2026B of A SecuritiesMaintainsNeutral—
10 July 2026B of A SecuritiesMaintainsNeutral$620 → $613
7 July 2026RBC CapitalMaintainsOutperform$701 → $704
7 July 2026RBC CapitalMaintainsOutperform—
7 May 2026RBC CapitalMaintainsOutperform—
7 May 2026Wells FargoUpgradeOverweight—
10 Apr 2026Morgan StanleyMaintainsEqual-Weight—
31 Mar 2026B of A SecuritiesMaintainsNeutral—
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026Wells FargoMaintainsEqual-Weight—
30 Mar 2026TD CowenMaintainsBuy—
23 Mar 2026Wells FargoMaintainsEqual-Weight—
12 Mar 2026Cantor FitzgeraldMaintainsOverweight—
5 Mar 2026UBSMaintainsBuy—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
26 Feb 2026OppenheimerMaintainsOutperform—
26 Feb 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UTHR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

UTHR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−3.6%
Analysts raising
3
Analysts cutting
3
Fundamentals

United Therapeutics Corp. (UTHR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.9×

Cheaper than 42% of US stocks

Price / sales
6.8×

Cheaper than 20% of US stocks

Price / book
3.3×

Cheaper than 32% of US stocks

EV / EBITDA
12.5×

Cheaper than 31% of US stocks

Growth & margins
Revenue growth (YoY)
−1.9%

Higher than 24% of US stocks

Earnings growth (YoY)
7.6%

Higher than 45% of US stocks

Gross margin
87.3%

Higher than 95% of US stocks

Operating margin
42.2%

Higher than 93% of US stocks

Net margin
41.6%

Higher than 95% of US stocks

Returns & dividend
Return on equity
19.3%

Higher than 80% of US stocks

Return on assets
11.6%

Higher than 94% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

UTHR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
UTHRUnited Therapeutics Corp.$21.4B
82
VTRSViatris, Inc.$18.7B
100
NBIXNeurocrine Biosciences, Inc.$15.2B
89
ZTSZoetis, Inc.$30.5B
42
ELANElanco Animal Health, Inc.$11.8B
98
ALKSAlkermes Plc$8.1B
60
HIMSHims & Hers Health, Inc.$6.6B
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own United Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UTHR news & analysis

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

Zacks Investment Research · 6 Aug 2026neutral

United Therapeutics reported second-quarter earnings that beat analyst estimates, while its revenues fell short of expectations. The company also continued advancing its Tyvaso and ralinepag programs, which are positioned to reshape future growth.

Why it matters — A UTHR watcher would care because the mixed quarterly results and the progress of the Tyvaso and ralinepag pipeline programs bear directly on the company's growth outlook.

United Therapeutics Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026neutral

United Therapeutics reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, with sales of its nebulized TYVASO therapy affected by competitive pressure. Executives said they expect stronger performance in the second half of the year but did not reaffirm or update previous 2026 revenue-growth expectations.

Why it matters — UTHR watchers would care because flat quarterly revenue, competitive pressure on TYVASO, and an unconfirmed growth outlook signal potential headwinds to the company's 2026 sales trajectory.

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

United Therapeutics Corporation held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha. The call covered the company's second-quarter 2026 financial results and business update.

Why it matters — A UTHR watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management commentary.

United Therapeutics (UTHR) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 5 Aug 2026neutral

Zacks reported on United Therapeutics' Q2 2026 earnings, noting that its revenue and EPS figures can be compared against Wall Street estimates and year-ago numbers.

Why it matters — This earnings recap provides a direct look at how UTHR's core financial metrics stack up against analyst expectations and prior performance.

United Therapeutics (UTHR) Q2 Earnings Surpass Estimates

Zacks Investment Research · 5 Aug 2026positive

United Therapeutics reported second-quarter earnings of $7.27 per share, surpassing the Zacks Consensus Estimate of $6.82 per share and up from $6.41 per share a year earlier.

Why it matters — UTHR watchers would note that quarterly earnings exceeded analyst expectations and improved year over year.

FAQ

Frequently asked questions about UTHR stock

What is the UTHR stock price forecast for 2026-2027?

The 15 Wall Street analysts covering United Therapeutics Corp. have a median 12-month price target of $685, with estimates ranging from $515 to $725. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is UTHR stock a buy right now?

Of the 15 analysts covering United Therapeutics Corp., 12 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks United Therapeutics Corp. 82 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank UTHR?

As at 15 Aug 2026, United Therapeutics Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will UTHR stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +37.1% from the last close, and Ticker Nerd's factor model ranks United Therapeutics Corp. 82 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the UTHR stock forecast for 2030?

No analyst covering United Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UTHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $515 to $725 over the next 12 months.

How has UTHR stock performed over the past year?

United Therapeutics Corp. returned +60.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does United Therapeutics Corp. do?

United Therapeutics Corporation is a biotechnology company specializing in therapies for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease, and other serious conditions. Founded in 1996 and headquartered in Silver Spring, Maryland, the company operates as a public benefit corporation focused on developing innovative treatments and technologies.

What is the latest news on UTHR?

The most recent item we track (Zacks Investment Research, 6 Aug 2026): "United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark". United Therapeutics reported second-quarter earnings that beat analyst estimates, while its revenues fell short of expectations. The company also continued advancing its Tyvaso and ralinepag programs, which are positioned to reshape future growth.

Company

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company specializing in therapies for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease, and other serious conditions. Founded in 1996 and headquartered in Silver Spring, Maryland, the company operates as a public benefit corporation focused on developing innovative treatments and technologies. Its FDA-approved therapeutic portfolio includes Tyvaso (treprostinil), available in both inhalation powder and nebulized formulations; Remodulin Injection; Orenitram Extended-Release Tablets; Adcirca (tadalafil); and Unituxin for treating PAH and related conditions. Beyond traditional pharmaceuticals, United Therapeutics pursues transformational initiatives through its subsidiary Lung Biotechnology PBC to address the critical shortage of transplantable organs through xenotransplantation and bioengineering technologies. The company maintains a robust commercial presence, distributing products through healthcare provider networks and partnerships. Its pipeline includes clinical programs exploring new therapeutic indications, delivery mechanisms, and organ manufacturing solutions. United Therapeutics serves patients, healthcare providers, and research institutions globally, combining steady commercial performance with visionary medical innovation.

CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. · 1,400 employees · United States · https://www.unither.com